A 52-Year-Old Woman with Intermediate-Risk Primary Myelofibrosis

home / case-based-peer-perspectives / a-52-year-old-woman-with-intermediate-risk-primary-myelofibrosis

Srdan Verstovsek, MD, PhD, provides insight on treatment of primary myelofibrosis, including ruxolitinib, and comments on some of the challenges, unmet needs, and future directions in the field.